Primary HCV Drug Resistance Mutations in Patients with Newly Diagnosed HIV Infection

Ostankova, Yu. V.; Валутите, Д. Э.; Зуева, Е. Б.; Серикова, Е. Н.; Щемелев, А. Н.; Boumbaly, S.; Balde, T.A.L.; Semenov, A.

doi:10.21055/0370-1069-2020-3-97-105

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, assessment of RAV in infected patients is important for monitoring treatment effectiveness and HCV epidemiology in Russia. Such studies of natural resistance mutations in untreated HCV patients may be of great importance [22][23][24][25]. The aim of this study was to investigate the prevalence of primary drug resistance mutations among patients with chronic hepatitis C (CHC) who had not previously received DAA treatment.…”

Section: Introductionmentioning

confidence: 99%

Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C

et al. 2022

Self Cite

View full text Add to dashboard Cite

The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients with chronic hepatitis C, yet high viral replication errors can lead to the development of resistance associated variants (RAVs). Thus, assessment of RAV in infected patients is necessary to monitor treatment effectiveness. The aim of our study was to investigate the presence of primary resistance mutations in the NS3 and NS5 regions of HCV in treatment-naive patients. Samples were taken from 42 patients with HCV who had not previously received DAA treatment. In the present study, we used the method for determining drug resistance mutations based on direct sequencing of the NS3, NS5A, and NS5B genes developed by the Saint Petersburg Pasteur Institute. Primary mutations associated with resistance were detected in 5 patients (12%). According to the Geno2pheno [hcv] 0.92 database, nucleotide substitutions were identified in various viral genes conferring resistance or decreased sensitivity to the respective inhibitors. This study has shown different mutations in the analyzed genes in patients with HCV who had not previously received DAA treatment. These mutations may increase the likelihood of treatment failure in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

HCV drug resistance mutations in HIV-infected patients

Reingardt,

Ostankova,

Anufrieva

et al. 2024

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

Aim. The aim of our work was to assess the mutations prevalence in the HCV drug resistance in the NS3, NS5A, NS5B genes in HIVinfected patients. Materials and methods. The material of the study was 157 blood plasma samples from HIV patients living in the Leningrad Region, with virological inefficiency of antiretroviral therapy. Samples were examined for the presence of anti-HCV antibodies and HCV RNA. In the case of detecting HCV RNA, amplification was carried out using a set of primers co-flanking the NS3, NS5A, and NS5B genes. After sequencing the nucleotide sequences of these genes, the virus subtype was determined and drug resistance mutations were detected. Results and discussion. The age of the patients varied from 18 to 65 and averaged 34.3 7.27 years. The number of men in the group prevailed compared to women - 71% and 28%, respectively. Antibodies to HCV were detected in 94.2% of HIV-infected persons. HCV RNA was detected in 98 (61.7%) patients. The distribution of HCV genotypes in this group was as follows: 1a 7% (n=7), 1b 53% (n=52), 2 2% (n=2), 3a 38% (n=37). The results of determining the viral load varied from 5.3x103 to 2.3x108 IU/ml. The nucleotide sequence of all three regions NS3, NS5A, NS5B was determined in 73 samples. In the study group, mutations associated with resistance of the hepatitis C virus to direct antiviral drugs in all regions were found in 16.6% of cases (n=26). There are 6 significant amino acid substitutions in the NS3 region, 15 and 10 significant amino acid substitutions in the NS5A and NS5B regions, respectively.

show abstract

Distribution of hepatitis С virus drug resistance mutations among patients with recurrence of the disease during therapy with direct antiviral drugs

Reingardt,

Ostankova,

Lyalina

et al. 2024

VIČ-infekc. immunosupr.

Self Cite

View full text Add to dashboard Cite

The aim of the study was to identify the prevalence of drug resistance mutations in the hepatitis C virus among patients with relapse of the disease on therapy with direct antiviral drugs.Materials and methods. The study material included 31 blood plasma samples from patients with chronic hepatitis C with relapse of the disease on therapy with direct antiviral drugs. Samples were screened for the presence of HCV RNA. In case of detection of HCV RNA, amplification was carried out using a set of primers jointly flanking the NS3, NS5A, NS5B genes. After sequencing the nucleotide sequences of these genes, the subtype of the virus was determined and drug resistance mutations were identified.Results and discussion. The age of the patients ranged from 33 to 62 and averaged 45.8±8.38 years. The number of men in the group prevailed compared to women — 21 (67%) and 10 (33%), respectively. Viral load determination results ranged from 3.1×103 to 4.2×107 IU/ml. The distribution of genotypes was as follows: 1a — 26% (n=8), 1b — 29% (n=9), 3a — 45% (n=14). The nucleotide sequence of the NS3, NS5A, NS5B regions was determined in all samples. Mutations associated with drug resistance were detected in 87% (n=27). In all identified cases, the mutations resulted in viral resistance to at least one drug included in the patient’s current treatment regimen. In one patient, amino acid substitutions were found in three regions at once, which led to the emergence of resistance to two drugs in the regimen.Conclusion. Conducting a preliminary examination of patients to identify mutations of drug resistance to direct antiviral drugs can affect the effectiveness of the planned treatment and the choice of the optimal regimen.

show abstract

Primary HCV Drug Resistance Mutations in Patients with Newly Diagnosed HIV Infection

Cited by 4 publications

References 26 publications

Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C

Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C

HCV drug resistance mutations in HIV-infected patients

Distribution of hepatitis С virus drug resistance mutations among patients with recurrence of the disease during therapy with direct antiviral drugs

Contact Info

Product

Resources

About